BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from its Chairman, Richard Staelin, PhD, highlighting sales growth, cost control, and strategic initiatives. The company reported a small profit for calendar year 2025, driven by disciplined cost control measures including office relocation and staff reductions to align with operational needs.
To boost revenue, BioElectronics launched targeted advertising campaigns directed at medical professionals and healthcare providers, aiming to expand clinical awareness of its RecoveryRx device among surgeons, pain specialists, and chiropractors seeking non-opioid pain management options. The company also expanded consumer-focused social media advertising targeting Generation X consumers to increase brand visibility for drug-free solutions for chronic musculoskeletal pain.
BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that could support future qualification for reimbursement under the federal NO PAIN Act initiative, which the company believes represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings with a former distributor that allegedly breached contractual obligations. The company remains committed to protecting its intellectual property and shareholder interests.
Additionally, BioElectronics has progressed its strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with Electrome placing its initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This milestone provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Despite challenges faced by emerging medical technology companies, Staelin expressed encouragement by the growing interest in non-drug pain management solutions and the long-term potential of the company's technology platforms. He believes BioElectronics is well positioned within the evolving electroceutical and non-opioid pain management markets.
